Article

Visual imaging platform offers specialized procedures

The Visera Digital Visual Imaging and Information platform from Olympusallows the physician to specialize each procedure while maintaining standardizationon the platform, creating greater operating efficiency for operating roomstaff and surgeons.

Related Videos
2 experts in this video
2 experts in this video
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
UGN-101 associated with favorable long-term durability in low-grade UTUC
February 12th 2025

UGN-101 associated with favorable long-term durability in low-grade UTUC

Hannah Clarke
The median duration of response was 47.8 months among patients who achieved an initial complete response.
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Danish Medicines Agency approves PSMA-PET imaging product for prostate cancer
February 11th 2025

Danish Medicines Agency approves PSMA-PET imaging product for prostate cancer

Hannah Clarke
Illuccix has been previously approved in the US, Australia, Canada, and Europe.
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Trends in urology: Arpeet Shah, MD, on challenges and opportunities in 2025
February 10th 2025

Trends in urology: Arpeet Shah, MD, on challenges and opportunities in 2025

Arpeet Shah, MD
Arpeet Shah, MD, highlights the shift toward precision medicine, ongoing work force challenges, the integration of AI, and more.
FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic
February 10th 2025

FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic

Hannah Clarke
The software generates heatmaps to help identify prostatic tumors that may have been missed on initial reads.
© 2025 MJH Life Sciences

All rights reserved.